Partnering with Lundbeck

Print

Partnerships are a key strategic objective for Lundbeck. This objective is achieved by obtaining increased value from our existing partnerships and by actively seeking and evaluating new opportunities at all times.

Over the last decade successful partnerships have been one of the main contributors to Lundbeck’s position as a leading CNS company (CNS - the central nervous system). The importance of partnerships is recognised throughout the organisation, and Lundbeck strives continuously to be the preferred partner of choice.

Why partner with Lundbeck?

1. Fully integrated company
Lundbeck is a fully integrated company and has more than 6000 employees with core competencies in research, clinical development, production, marketing and sales. Partnered products have successfully been integrated into our value chain – from preclinical to marketed products.

2. Proven track record of bringing products to the market
The majority of Lundbeck’s currently marketed products are based on successful internal innovations and external development opportunities. As a result, Lundbeck has a strong late-stage pipeline with five products in phase III / pre-registration with expected launch within the next few years.

The success of our pipeline is due to Lundbeck's 1,200 dedicated R&D staff who are skilled in development and focused on project teams. In 2011 Lundbeck invested 20% of its total revenue in R&D.

3. Proven track record of commercial success
Owing to our strong commercial platform and our presence in over 100 countries, Lundbeck has created commercial successes for our products. Our anti-depressant, Cipralex/Lexapro, is value market leader in 43 countries. Moreover Lundbeck markets pharmaceuticals for the treatment of Alzheimer’s disease, epilepsy, Huntington’s disease, insomnia, Parkinson’s disease and schizophrenia/bipolar disorder.

This success is built on a large global sales and marketing infrastructure with more than 3,000 employees and strong regional commercial capabilities. Our committed commercial organisation is dedicated to bringing therapies to the patients that need them.

4. Dedicated to brain disorders
Building on its own innovations and external licensing agreements, Lundbeck has more than 50 years’ experience within brain disorders. Our R&D and commercial teams are dedicated to brain disorders, and we have a strong network among CNS key opinion leaders, specialists as well as GPs.

Lundbeck’s strategy is to strengthen our position as a leading company within brain disorders. Brain disorders are among the largest therapeutic categories in the world, the patient population is expected to increase over the coming years and the unmet medical need in this area is substantial.

5. Flexible and fast decision-making on partnerships
Lundbeck’s top management is committed to partnerships and has developed a process to ensure structured and fast decision making when evaluating new partnering opportunities.

You are now leaving lundbeck.com.au. Please note that the information contained in the site you are linking to may not be fully compliant with the Australian regulatory environment and that product related information should be checked against the corresponding Australian consumer medicine information or by asking your doctor. Any information provided should be discussed with your health care professional and does not replace the advice and treatment of your doctor. We hope you will visit us again soon.